Extension of Director's Options Exercise Period

RNS Number : 8289I

Epistem Holdings plc

30 March 2015

 



For Release            30 March 2015

Epistem Plc

("Epistem" or "the Company")

Extension of Director's Options Exercise Period

The Board of Epistem (AIM: EHP), the personalized medicine and biotechnology company, announces that on 27 March 2015 the Remuneration Committee agreed to a two year extension until 30 March 2017 in respect of 78,000 share options exercisable at £1.29 per share held by Non-executive director, Dr Robert Nolan, which were issued on 31 March 2005 and are fully vested.

Together with his other options, Dr Robert Nolan holds fully vested options over a total of 93,528 ordinary shares of £0.015p, representing 0.8% of the current issued share capital of the Company.

For further information contact:

Epistem Plc

Matthew Walls, Chief Executive Officer                                                              ++44 161 606 7258                             

John Rylands, Finance Director                                               

Peel Hunt LLP 

James Steel                                                                                                            ++44 207 418 8900   

Clare Terlouw                                                               

Wallbrook PR

Mike Wort

Anna Dunphy                                                                                                       ++44 207 933 8780

Notes for editors

About Epistem

Epistem (http://www.epistem.co.uk) is a personalised medicine and biotechnology company commercialising its technology and expertise in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative diagnostics and pharmacogenomics (Genedrive^®), target discovery of novel therapeutics and contract research services for drug development companies. Epistem operates three divisions, Personalised Medicine (Diagnostics and Pharmacogenomics), Contract Research Services and Novel Therapies.

Genedrive® (http://www.genedrive.com) provides a major advance in next-generation molecular diagnostic testing by providing a handheld, rapid, low-cost, simple-to-use 'point of care' device with high sensitivity and specificity for diagnosis of infectious diseases. Genedrive® aims to provide a 'gold standard' identification of tuberculosis and antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.

Epistem's Genedrive® platform has applications across a wide range of bacterial, viral and fungal and somatic mutation diseases for which Epistem is developing a menu of diagnostic tests.

 

END

 

 

RDSZMGFFRGNGKZG